Compare Aecom (ACM) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs ARK Genomic Revolution ETF — how do they compare? Aecom trades at $63.5 (market cap $7.86B), while ARK Genomic Revolution ETF trades at $44.47. The key difference: Aecom pays a 1.95% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Aecom nearer its low. Which is the better fit depends on your goals.
| ACM | ARKG | |
|---|---|---|
Market Cap | $7.86B | — |
Sector | Industrials | Sector/Thematic |
52-Week High | $134.35 | $44.69 |
52-Week Low | $61.04 | $24.02 |
Enterprise Value | $10.05B | — |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM's stock trades at $63.61, down 5.13% amid a bearish technical outlook and mixed earnings, including a Q2 2026 loss of $0.50 per share versus a $1.46 estimate. Revenue growth has been volatile, with 2025 revenue at $16.14 billion and net income of $561.77 million, but profitability metrics like ROE of -3.89% and net margin of 1.87% indicate challenges. Recent news highlights a securities fraud investigation and a $337 million pre-tax charge from project delays, offset by a new Lisbon Airport design win.
The stock faces headwinds from weak technical signals and earnings misses, but analyst consensus remains bullish with a $83.17 price target, suggesting 31% upside. Risks include legal scrutiny, execution delays, and margin pressure, while institutional holdings and backlog growth offer stability. Investors should weigh the high analyst optimism against fundamental weaknesses and ongoing volatility.
ARK Genomic Revolution ETF (ARKG) trades at $44.69, up 0.31% with a bullish technical signal from moving averages but bearish oscillators. The ETF focuses on small- and mid-cap biotech stocks with 59% concentration in top 10 holdings. Recent news highlights ARKG's recovery from a 15% July correction, with biotech sector strength driven by FDA developments and M&A activity.
ARKG offers exposure to genomic innovation with improving valuations but faces sector volatility risks. The ETF's long-term EPS growth rate of 10.7% supports growth potential, though concentrated holdings and technical overbought signals warrant caution amid broader market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
